Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma

Is exposure of patients with newly diagnosed glioblastoma to proton pump inhibitors associated with survival outcomes?This meta-analysis of individual data from 2981 patients enrolled into 5 prospective clinical trials found that the use of proton pump inhibitors that are potent activators of aldehyde dehydrogenase 1 A1 was associated with inferior survival outcomes, independently of promoter methylation status and steroid use. No such association was observed with other antacid medications.These findings suggest that PA-PPI use should be discouraged in patients with glioblastoma.

Corresponding Author: Emilie Le Rhun, MD, PhD, Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland (emilie.lerhun@usz.ch).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.